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ABSTRACT 
 
Trace amines (2-phenylethylamine, p-tyramine, p-octopamine and tryptamine) are 
endogenous compounds structurally similar to the monoamine neurotransmitters and 
distributed throughout the nervous systems of vertebrates. However, they are not thought 
to be stored in synaptic vesicles, nor released in an activity-dependent manner. Their 
synthesis, however, is regulated with the enzyme aromatic L-amino acid decarboxylase 
being a rate limiting factor. Distinct post-synaptic effects of trace amines have been 
demonstrated and a family of G-protein-coupled Trace Amine-Associated Receptors 
(TAAR) has been identified. The TAAR protein, though, is poorly translocated to the cell 
membrane and remains intracellular. Hence, in order to bind to post-synaptic TAAR, 
trace amines have to cross cell membranes. This was previously thought to occur by 
simple diffusion. Recent computer simulations have, however, predicted a high-energy 
barrier associated with this process.  
Here the membrane passage of trace amines in the absence of transporters has been 
measured directly for the first time using the Fluorosome system. The trace amines 
tyramine (p<0.01), and tryptamine (p<0.001), had significantly greater membrane 
permeability than the comparable monoamine neurotransmitters, with trace amine 
permeability half-lives under 15 seconds. The effect of membrane transporters on the 
permeability of a representative trace amine (tyramine) and neurotransmitter (dopamine) 
was examined in Caco-2 and synaptosome studies. Tyramine accumulation (≈7-8% of 
administered concentration) was approximately twice that of dopamine (3-4%) in Caco-2 
cells. Equilibration of both tyramine and dopamine occurred in less than 10 minutes. In 
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synaptosomes both tyramine and dopamine uptake equilibrated within 1 minute. 
Tyramine release from synaptosomes was significantly faster (p<0.001) than that of 
dopamine. Dopamine release in depolarized membranes was significantly faster (p<0.01, 
F = 6.95) while tyramine release was significantly slower (p< 0.05, F = 5.86) than in non-
depolarized membranes. Release from synaptosomes was significantly slower than 
Fluorosome membrane passage for both tyramine (p<0.0002, F = 13.63) and dopamine 
(p<0.0001, F = 56.77) indicating the involvement of processes other than simple 
diffusion. In conclusion, the trace amines are more permeable than the corresponding 
neurotransmitters both in the absence and presence of transporters. 
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1 INTRODUCTION 
Trace amines are a group of endogenous amines found in the central nervous system of 
all species studied so far (Philips et al., 1978; D’Andrea et al., 2003; Berry, 2004; Jacob 
and Presti, 2005). These include 2-phenylethylamine (PE), para-tyramine, tryptamine, 
para-octopamine and para-synephrine. They have structural similarities with 
neurotransmitters such as DA, noradrenaline and serotonin (5-HT) (Figure 1). However, 
in vertebrates the trace amines have very low concentrations, usually in the range of 0.1-
10 nM, which is less than 1% of neurotransmitter concentrations (Durden et al., 1973; 
Durden and Philips, 1980; Durden and Davis, 1993), hence, the name trace amines. 
In invertebrates the trace amines are found in higher concentrations and, because of this, 
octopamine and tyramine function as primarily neurotransmitters (Axelrod and Saavedra, 
1977; David and Coulon, 1985; Evans and Robb, 1993; Roeder, 1999; Saraswati et al., 
2004). In vertebrates the trace amines are not thought to be neurotransmitters mainly due 
to the fact that they are not stored in synaptic vesicles (Juorio et al., 1988), are not 
released in an activity-dependent manner (Dyck, 1989) and moreover do not affect 
neuronal excitability at physiological levels (Jones, 1981; Harris et al., 1988; Berry et al., 
1994). However, the synthesis of trace amines is regulated (Paterson et al., 1990) and 
they alter the neuronal responses of neurotransmitters (Henwood et al., 1979; Jones and 
Boulton, 1980; Lundberg et al., 1985; Paterson, 1993).  
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Figure 1: Molecular structure of selected neurotransmitters and trace amines 
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This suggests that trace amines have physiological significance, an assertion supported by 
the discovery of Trace Amine-Associated Receptors (TAAR), which are intracellular G-
protein-coupled receptors (GPCRs) selectively activated by trace amines (Borowsky et 
al., 2001; Bunzow et al., 2001). Post-synaptic effects of trace amines are presumed to be 
mediated through TAAR (Berry, 2004; Sotnikova et al., 2004; Lindeman et al., 2008) and 
for these to occur, the trace amines would have to cross the cell membranes. This 
membrane passage was assumed to occur by simple diffusion (Paterson et al., 1990; 
Tchercansky et al., 1994; Berry, 2004), but computer simulation studies suggest a high-
energy barrier associated with diffusion across a lipid bilayer (Berry et al., 2011). Trace 
amines have also been implicated in a number of neurological and psychiatric disorders 
(Berry, 2007) and TAAR are potently activated by a number of drugs of abuse (Bunzow 
et al., 2001; Reese et al., 2007). Determination of the mechanisms by which trace amines 
interact with their receptors is of importance for a better understanding of trace amine 
functioning under physiological and pathological conditions. This will be addressed in 
this thesis by determining the ability of trace amines to cross lipid bilayer membranes 
both in the absence and presence of endogenous transporter proteins. Furthermore, the 
membrane passage will be compared to that of the more widely studied monoamine 
neurotransmitters.  
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2 LITERATURE REVIEW 
2.1 SYNTHESIS OF TRACE AMINES 
 
The trace amines are synthesized by initial decarboxylation of the aromatic amino acids 
L-phenylalanine, L-tyrosine and L-tryptophan by aromatic L-amino acid decarboxylase 
(AADC; EC 4.1.1.28) in a single enzymatic step (Boulton, 1982) (Figure 2). Although 
AADC is not the rate-limiting factor in the synthesis of neurotransmitters, it is in the 
synthesis of trace amines as it is the only enzyme involved in their synthesis (Saavedra et 
al., 1974; Dyck et al., 1983; Berry et al., 1996). 
2.1.1 RELATIONSHIP BETWEEN TRACE AMINE LEVELS, AADC ACTIVITY 
AND NEUROTRANSMITTERS 
Agonists at DA and noradrenaline receptors cause a decrease in AADC activity and 
subsequent decrease in the trace amine levels (Rossetti et al., 1990; Hadjiconstantinou et 
al., 1993; Zhu et al., 1993), while antagonists cause an increase in AADC activity and the 
levels of trace amines (Zhu et al., 1992; Cho et al., 1997; Neff et al., 2006). These 
changes in AADC activity however, were insufficient to cause alterations in the levels of 
neurotransmitters. Further, treatments that increase the synaptic levels of 
neurotransmitters also decrease AADC activity and trace amine levels (Juorio et al., 
1991). 
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Figure 2: Endogenous routes of synthesis for trace amines and monoamine 
neurotransmitters.   
AADC: Aromatic L-amino acid decarboxylase;  
DBH: Dopamine β-hydroxylase;  
PNMT: Phenylethanolamine N–methyl transferase;  
TH: Tyrosine hydroxylase;  
PH: Phenylalanine hydroxylase 
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For example, amphetamine increases extracellular DA levels (Carboni et al., 2001), 
causes a decrease in AADC activity (Buckland et al., 1996) and decreases accumulation 
of the trace amine PE (Boulton, 1982). Also reserpine, which causes depletion of 
neurotransmitters (Wessel and Joh, 1992), increases AADC activity and the accumulation 
of PE (Juorio, 1988). Thus, drugs that increase stimulation of neurotransmitter receptors 
cause a decrease in the AADC activity and a subsequent decrease in trace amine levels. 
Treatments that decrease stimulation of neurotransmitter receptors enhance AADC 
activity and thereby increase trace amine levels. Hence, the trace amine levels appear to 
be modulated by regulation of AADC activity in response to synaptic neurotransmitter 
levels. 
2.2 DEGRADATION OF TRACE AMINES 
 
The trace amines are inactivated primarily by oxidation of the amino group by the 
enzyme monoamine oxidase (MAO; EC 1.4.3.4) (Philips and Boulton, 1979). There are 
two isoforms of MAO: MAO-A and MAO-B (Shih and Chen, 2004). Each of these 
isoforms displays characteristic preference for particular trace amines. For example, 2-
phenylethylamine is primarily oxidized by MAO-B (Yang and Neff, 1973) whereas other 
trace amines are acted upon by both MAO-A and MAO-B (Philips and Boulton, 1979; 
Durden and Philips, 1980). The rate of metabolism is very high, giving trace amines a 
high turnover rate, with an endogenous half-life of approximately 30 seconds (Durden 
and Philips, 1980). This is also consistent with the apparent lack of storage of trace 
amines (Juorio et al., 1988). 
 7 
 
2.3 FUNCTIONAL EFFECTS OF TRACE AMINES 
 
Both pharmacological and physiological effects of trace amines have been described. In 
addition trace amines have been implicated as playing a causative role in a number of 
toxicological and pathophysiological conditions. 
2.3.1 Indirect Sympathomimetic Effects. 
The effects of trace amines have been described as indirect sympathomimetic or 
amphetamine-like (Parker and Cubeddu, 1988; Paterson, 1993; Barroso and Rodriguez, 
1996). These effects require much higher levels of trace amines than normal, which is 
micromolar levels compared to the usual nanomolar levels (Reynolds, 1979; Baud et al., 
1985; Parker and Cubeddu, 1988; Paterson, 1993; Barroso and Rodriguez, 1996). Here 
they increase the synaptic transmitter concentrations by blocking re-uptake processes and 
displacing vesicular stores of neurotransmitters (Burchett and Hicks, 2006). These effects 
result in a number of pharmacological responses and were previously thought to be the 
mechanism of amphetamine action (Burchett and Hicks, 2006). For example, in CNS the 
trace amines produce responses similar to amphetamine showing increased alertness, 
euphoria, decreased appetite, irritability, insomnia and tremor (Zhu and Juorio, 1995). In 
the cardiovascular system effects such as tachycardia and vasomotor effects leading to 
both hypertension and hypotension are seen (Horn and Snyder, 1972). While these effects 
may have pharmacologic importance, the high concentrations of trace amines required for 
their induction, make them unlikely to be of physiological relevance. 
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2.3.2 Physiological Effects 
Several electrophysiological iontophoretic studies have been done on rat brain to 
determine the effects of trace amines on neurotransmission (Henwood et al., 1979; Jones 
and Boulton, 1980; Lundberg et al., 1985; Paterson, 1993). Trace amines have been 
shown to modify the in vivo responses of neurotransmitters at doses that induce no 
change in electrophysiological properties alone. Table 1 summarizes the interaction of 
various trace amines with different neurotransmitters. PE potentiates the response of 
dopamine (DA) and its agonists (Harris et al., 1988; Paterson et al., 1990; Berry et al., 
1994) and noradrenaline (NA) (Jones, 1982b; Paterson, 1988; Paterson, 1993). No effects 
are seen with 5-HT (Jones, 1982b), acetylcholine (Jones, 1982b; Paterson, 1993), 
gamma-amino butyric acid (GABA) (Jones, 1982b; Paterson, 1988) or glutamate (Jones, 
1982b). However, one group has reported PE reduced GABA receptor mediated pre-
synaptic inhibition (Brancucci et al., 2004; Berretta et al., 2005). Similarly p-tyramine 
potentiates responses of DA (Jones and Boulton, 1980; Harris et al., 1988), and NA 
(Harris et al., 1988) with no effects on 5-HT (Jones and Boulton, 1980), glutamate (Jones 
and Boulton, 1980) or GABA (Harris et al., 1988) responses. Interactions with 
acetylcholine (Ach) have not been investigated. Very little is known about the 
interactions of tryptamine (TRYP), octopamine (OCT) and synephrine (SYN) with 
neurotransmitters. TRYP interactions with 5-HT (Jones, 1982a; Paterson and Boulton, 
1988) and Ach (Jones, 1982a) have been studied, but with other transmitters, the effects 
are unknown. TRYP enhanced the depressant responses to exogenous 5-HT when applied 
with ejecting currents that did not affect the cell firing rate (Jones, 1982a). In contrast, 
TRYP inhibited the excitatory responses of 5-HT in the nucleus raphe medianus at low 
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concentrations, or converted them to inhibitory effects (Jones, 1982a). OCT enhances the 
effect of NA with no effects on DA and 5-HT (Jones, 1983). 
 
Table 1: Interactions of Neurotransmitters and Trace amines 
+ = Neurotransmitter response potentiated. 
+/- = Neurotransmitter response potentiated or decreased. 
- = No Effect. 
Blank = Effects not studied. 
 
These effects of trace amines are post-synaptic. The exact mechanism is not known but 
when the vesicular stores of neurotransmitters are depleted by pre-treatment with 
reserpine, the trace amines still potentiated the responses of iontophoretically applied 
neurotransmitters without affecting the spontaneous firing rate (Paterson, 1993). This 
suggests the effects of trace amines are not dependent on endogenous neurotransmitter 
stores and as such are not due to the indirect sympathomimetic effects of high doses. 
     PE TYRA TRYP OCT SYN 
DA + +  _  
NA + +  +  
5-HT _ _ +/- _  
ACH _  _   
GABA -/+ -/+    
GLUTAMATE _ _    
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Effects are also seen if pre-synaptic terminals are lesioned, providing direct evidence that 
the effects are post-synaptic (Paterson, 1988).  
Effects are also seen if endogenous levels of PE are altered. Trace amines are not stored 
in the synaptic vesicles (Juorio et al., 1988) and are thought to be released directly upon 
their synthesis and this could be mainly because they were thought to diffuse across 
membranes (Paterson et al., 1990; Tchercansky et al., 1994; Berry, 2004). Thus synaptic 
levels of trace amines can be modified by altering their synthesis and degradation. 
Endogenous levels of PE were increased by inhibiting the degradative enzyme MAO-B 
with deprenyl (Paterson et al., 1991; Berry et al., 1994). The increase in endogenous 
levels did not affect the spontaneous neuronal activity but in the presence of 
dopaminergic activity, elevated PE levels significantly affected neuronal responsivity, 
seen as increased sensitivity to dopamine (Paterson et al., 1991; Berry et al., 1994). 
Further, on application of an AADC inhibitor the levels of endogenous PE decreased, and 
the neuronal sensitivity was returned to the pre-deprenyl administration levels (Paterson 
et al., 1991; Berry et al., 1994). Post-synaptically PE is hypothesized to interact with a 
TAAR (Berry, 2004), but it is not known which one(s).  
The electrophysiological effects, combined with the previously described regulation of 
trace amine synthesis in response to neurotransmitter receptor activation, suggest that 
trace amines can function as an endogenous mechanism for regulating neurotransmitter 
activity in order to maintain basal neuronal tone. 
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2.3.3 Trace Amine Associated Receptor Mediated Effects 
Two separate groups (Borowsky et al., 2001; Bunzow et al., 2001) discovered the 
existence of GPCRs activated by trace amines. This discovery has highlighted many new 
dimensions regarding the trace amines, by providing a target through which trace amine 
effects can be mediated. TAARs are a sub family of the rhodopsin class of GPCR 
(Lindemann et al., 2005) that are distinct from the invertebrate tyramine and octopamine 
receptors (Niimura and Nei, 2005; Hashiguchi and Nishida, 2007; Hussain et al., 2009) 
and also other biogenic amine receptors (Lindemann et al., 2005; Hussain et al., 2009).   
The most recent classification (Hussain et al., 2009) has identified 28 sub-families of 
vertebrate TAAR. TAAR1-9 are seen in multiple vertebrate species and TAAR10-28 are 
fish specific. Multiple isoforms of individual TAAR are present, many of which appear 
species specific (Hussain et al., 2009). These subtypes can be further divided into major 
clades referred to as class I to III. Class I (TAAR1, 10-11,21,27) and class II (TAAR2-
9,12-13) contain both tetrapod and teleost genes and class III (14-20, 22-26, 28) are 
restricted to teleosts (Korsching, 2009). All TAAR are single exon genes (Lindemann et 
al., 2005) and in non-aquatic vertebrates they are clustered onto a single chromosome 
(Lindemann et al., 2005). In fish which have a much larger pool of TAAR, these genes 
are scattered over multiple chromosomes (Hussain et al., 2009). 
Large species variation between the vertebrates also exists in terms of different numbers 
of isoforms as well as pseudogenes (Table 2). Humans have 6 functional TAAR genes 
with 3 pseudogenes, while the chimpanzee has only 3 functional genes but 6 pseudogenes 
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(Lindemann et al., 2005). Similarly, in rat and mouse there are 17 and 15 functional 
TAAR and 2 pseudogenes, respectively (Lindemann et al., 2005). 
 
 
Table 2: Species variation in TAAR showing number of functional and pseudogenes in 
different species. 
 
 
Of the different TAAR only TAAR 1 and TAAR 4 have so far been shown to be 
activated by endogenous trace amines (Bunzow et al., 2001; Borowsky et al., 2001; 
Lindemann and Hoener, 2005; Grandy, 2007; Hussain et al., 2009), with TAAR1 the only 
receptor studied in detail. Endogenous ligands for the other TAAR have not been 
identified. 
TAAR are distributed throughout the body. TAAR1 distribution is described in detail 
below (Section 2.3.3.1). TAAR 6 and TAAR 8 are found in the kidney and amygdala 
(Borowsky et al. 2001) and TAAR 9 found in kidney, pituitary and skeletal muscles 
 Functional TAAR Genes Pseudogenes 
Human 6 3 
Chimpanzee 3 6 
Rat 17 2  
Mouse 15 2 
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(Vanti et al., 2003). TAAR have also been classified as a novel class of olfactory 
receptors in vertebrates (Liberles, 2009). 
2.3.3.1 TAAR1 
TAAR1 is activated by PE, tyramine, catecholamine-O-methyl metabolites of 
catecholamine neurotransmitters and iodothyronamines (Borowsky et al., 2001; Bunzow 
et al., 2001; Scanlan et al., 2004; Tan et al., 2008). Drugs of abuse like d-amphetamine, l-
amphetamine, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA; 
‘ecstasy’) also potently activate TAAR1 (Bunzow et al., 2001; Lindemann and Hoener, 
2005) along with the hallucinogenic dihydroergotamine and N,N-dimethyltryptamine 
(Bunzow et al., 2001). Unlike neurotransmitter receptors, TAAR are intracellular 
(Bunzow et al., 2001; Miller et al., 2005; Wolinsky et al., 2007; Grandy, 2007; Reese et 
al., 2007; Wainscott et al., 2007; Barak et al., 2008). This requires membrane passage of 
endogenous ligands for post-synaptic effects to be mediated. The level of expression of 
TAAR is also lower than neurotransmitter receptors (Borowsky et al., 2001). 
TAAR1 is coupled to the Gs protein leading to activation of adenylate cyclase and cAMP 
production (Borowsky et al., 2001; Bunzow et al., 2001). Recent studies suggest coupling 
through G-protein-gated potassium (GIRK) channels (Bradaia et al., 2009) also occurs. 
TAAR1 signaling is also enhanced by monoamine transporters (Xie et al., 2007; Xie et 
al., 2008) and it was suggested that intracellular TAAR1 receptors may redistribute to the 
cell membrane as part of their signal transduction cascade (Miller, 2011).  
In mouse CNS TAAR1 is distributed across the limbic system, monoaminergic cell body 
regions and their projection areas like the locus coeruleus, substantia nigra, ventral 
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tegmental area, dorsal raphé, striatum and basal ganglia (Borowsky et al., 2001, 
Lindemann and Hoener, 2005). In rat CNS TAAR1 is also present throughout the brain, 
with highest expression in the olfactory bulb, nucleus accumbens, cortical regions, 
substantia nigra, ventral tegmental area, cerebellum and medulla (Lindemann and 
Hoener, 2005). In the periphery TAAR1 is expressed in liver, kidney, gastrointestinal 
tract, spleen, pancreas and heart (Bunzow et al, 2001, Lindemann and Hoener, 2005). 
TAAR1 have also been found in blood vessels (Borowsky et al., 2001; Broadley, 2010) 
and leukocytes (Nelson et al., 2007). In rhesus monkey TAAR1 is expressed in the 
primary dopaminergic areas such as the substantia nigra and striatum (Xie et al., 2007). 
Of these various locations the amygdala region in rat, mouse and human CNS contain the 
highest levels of TAAR1 mRNA (Borowsky et al., 2001). Thus TAAR1 is widely 
expressed in primary dopaminergic areas of brain and suitably located to modulate the 
locomotor, emotional and behavioural responses which are related to dopaminergic 
activity in these areas. 
Several studies have determined the potencies of trace amines at TAAR1. PE and 
tyramine are the more potent having EC50 values in the range of 400-900 nM for PE and 
70-1100 nM for tyramine (Borowsky et al., 2001; Bunzow et al.,
 
2001; Lindemann and 
Hoener, 2005; Miller et al., 2005; Navarro
 
et al., 2006; Wolinsky et al., 2007; Grandy, 
2007; Reese et
 
al., 2007; Wainscott et al., 2007; Barak et al., 2008; Lewin
 
et al., 2008). 
Octopamine and TRYP show relatively weaker activity at rat and human TAAR1 
(Borowsky
 
et al., 2001; Bunzow et al., 2001; Lindemann and Hoener, 2005;
 
Miller et al., 
2005; Navarro et al., 2006; Wainscott et al.,
 
2007; Barak et al., 2008). PE is moderately 
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more potent than tyramine at mouse and human TAAR1 whereas tyramine is the more 
potent in the rat (Grandy, 2007). 
Bunzow et al. (2001) also observed that the O-methyl metabolites of catecholamine 
neurotransmitters like 3-methoxytyramine (3-MT), 4-methoxytyramine (4-MT), 
normetanephrine and metanephrine are potent agonists at rat TAAR1. The same finding 
regarding 3-MT and 4-MT was confirmed at human TAAR1 (Wainscott et al., 2007; 
Barak et al., 2008). 3-MT is an extracellular metabolite of dopamine formed when 
dopamine is acted upon by catechol-O-methyl transferase (COMT). These O-methyl 
metabolites were previously considered inactive compounds and tissue concentrations 
considered as a marker of extracellular dopamine levels (Kehr, 1976). Activation of 
TAAR1 by O-methyl metabolites is consistent with the trace amine system responding to 
the extra-cellular neurotransmitter levels (see section 2.1.1). 
Another endogenous agonist is 3-iodothyronamine (T1AM) which is derived from 
thyroid hormone by decarboxylation and deiodination (Scanlan et al., 2004; Hart et al., 
2006;
 
Tan et al., 2007). T1AM is potent at rat, mouse (Scanlan
 
et al., 2004; Tan et al., 
2007) and human (Hart et al., 2006;
 
Grandy, 2007) TAAR1 with low nanomolar EC50 
values. Other thyronamines such as 3,5-diiodothyronamine and 3,5,3-triiodothyronamine 
also activate TAAR1 but with much lower potency (Tan et al., 2007; Tan et al., 2008, 
Tan et al., 2009). T1AM also interacts with a number of other GPCR and membrane 
proteins with similar affinity (Zucchi et al., 2006; Ianculescu et al., 2009; Ianculescu and 
Scanlan, 2010) including DA and NA transporters thereby causing inhibition of reuptake 
and also interacts with vesicular monoamine transporter-2 (VMAT2) (Snead et al., 2007) 
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and the role of TAAR in the effects of thyroid hormones has not yet been studied in 
detail.  
Amphetamine has a similar molecular structure to the trace amines PE and p-tyramine 
and stimulates cAMP production through rat, rhesus monkey and human TAAR1  (Miller 
et al., 2005; Wolinsky
 
et al., 2007; Reese et al., 2007; Wainscott et al., 2007; Xie
 
and 
Miller, 2007; Xie et al., 2007; Barak et al., 2008; Lewin
 
et al., 2008). EC50 values are 
comparable to PE (210 nM for R-amphetamine and 440 nM for S-amphetamine). 
Methamphetamine, MDMA and the hallucinogenic amphetamine 2-amino,1-[2,5-
dimethoxy-4-iodophenyl]-propane (DOI) are slightly less potent than amphetamine 
(Bunzow et al., 2001). TAAR1 is now proven to be a validated target for amphetamine 
and methamphetamine (Reese et al., 2007). The exact role of TAAR1 in the toxicological 
effects of these drugs of abuse is not yet known. Recently, one TAAR1 antagonist 
EPPTB (RO5212773) (Bradaia et al., 2009; Stalder et al., 2011) has been identified but 
this is only active in mouse. A synthetic TAAR 1 agonist, RO5166017, has also been 
described recently (Revel et al., 2011) which shows high affinity for mouse, rat, primate 
and human TAAR1. A TAAR1-mediated modulation of dopaminergic and serotonergic 
activity was seen following administration of RO5166017 to brain slice preparations 
(Revel et al., 2011). 
Presynaptically trace amines bind to TAAR1 receptors and have effects that could lead to 
enhanced responses to neurotransmitters (Xie and Miller, 2007; Xie and Miller, 2008; 
Xie and Miller, 2009). A TAAR1 mediated inhibition of dopamine re-uptake via the 
dopamine transporter has been reported, leading to increases in dopamine levels in the 
synapse (Miller, 2011). In the presence of a dopamine receptor reserve, this could be 
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expected to lead to an increase in dopamine receptor activation. As such, trace amines 
can regulate neurotransmitter re-uptake proteins at low doses via an interaction with 
TAAR1, and at high doses through a direct inhibition of the transporter. Further, trace 
amines can therefore potentiate dopaminergic responses both pre-synaptically and post 
synaptically. Similar TAAR1 mediated effects were also observed at noradrenaline (Xie 
and Miller, 2007; Xie and Miller, 2008; Xie et al., 2008) and 5-HT (Xie and Miller, 2007; 
Xie et al., 2008) transporters. 
Studies have also demonstrated an interaction between TAAR1 and D2 dopamine 
receptors (Xie et al., 2007; Bradia et al., 2009; Espinoza et al., 2011). Using TAAR1 
knock-out (KO) mice the effects of D2 mediated responses of dopamine were found to be 
increased (Bradia et al., 2009). On the other hand when D2 receptors were blocked with 
an antagonist, TAAR1 cAMP-mediated signaling was increased (Espinoza et al., 2011). 
Thus TAAR1 and D2 receptors can modulate the other’s activity. In contrast the TAAR1 
ligand PE has been reported to have no effect on agonist and antagonist interactions at D1 
dopamine receptors (Berry, 2004).  
2.3.4. Toxicologic and Pathophysiological Effects     
2.3.4.1 Toxicologic 
2.3.4.1.1 Drugs of Abuse 
As described above amphetamine-related drugs of abuse are agonists at TAAR1 (Bunzow 
et al., 2001, Reese et al., 2007). Other drugs of abuse, for example cocaine, however, do 
not bind to TAAR1 (Revel et al., 2011). TAAR1 KO mice have been shown to have 
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increased sensitivity to the locomotor stimulating effects of d-amphetamine (Wolinsky et 
al., 2007; Lindemann et al., 2008) and show higher increases in extracellular monoamine 
(example dopamine) levels after d-amphetamine administration (Wolinsky et al., 2007). 
Also methamphetamine induced behaviours in TAAR1 KO mice were seen to increase 
(Miller, 2011). This suggests a role for TAAR1 as a modulator of amphetamine mediated 
effects (Miller, 2012).  
2.3.4.1.2 Cheese Effect 
The “cheese effect” is seen in some patients taking MAO inhibitors. The hypertensive 
crises (Blackwell, 1963) known as the cheese effect reflects an increase in blood 
pressure, severe headache, and sometimes brain hemorrhage or heart failure (Smith, 
1980). Patients receiving MAO inhibitors will have increased levels of trace amines 
compared to normal individuals. When such sensitized patients take foodstuffs, such as 
aged cheeses, that are rich in tyramine, the levels may increase far in excess of 
physiological levels. Trace amines have been found in fermented products like cheese 
and especially many manufactured cheese products (El-zayat and El-Bagoury, 1988; 
Stratton et al., 1991). The discovery of TAAR present in the vasculature (Zucchi et al., 
2006; Broadley, 2010) raises the possibility that these effects are TAAR-mediated rather 
than being through indirect sympathomimetic actions as was previously assumed 
(Maguire et al., 2009). 
2.3.4.1.3 Migraine 
Red wine, cheese and chocolate are frequently implicated in precipitating migraine 
(Peatfield et al., 1984; Fukui et al., 2008). Such food induced migraine has been 
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hypothesized to be due to foodstuffs which are high in trace amine levels (Hannington, 
1967; Vaughan, 1994). For example, red wine has been shown to have non-volatile trace 
amines like tyramine and TRYP and volatile amines like PE (Ancin--Azpilicueta et al., 
2008). As described earlier (see Section 2.3) the trace amines and other amines are 
metabolized by MAO. In wine, substances like ethanol and acetaldehyde inhibit MAO, 
and thus increase the effects of trace amines (Brink et al., 1990). Red wine has been 
shown to contain more trace amines than white (Ibe et al., 1991). Chocolates also contain 
trace amines especially PE (Ziegleder et al., 1992). The most important trace amines and 
other biogenic amines found in cheese are tyramine, TRYP, PE, histamine, putrescine 
and cadaverine (Joosten, 1988a,b; Tawfik et al., 1992).  
2.3.4.2 Pathophysiological 
Trace amines have been associated with various human diseases particularly 
neuropsychiatric diseases like schizophrenia, depression and drug abuse and addiction 
(Berry, 2007). The physiological effects suggest they may also have relevance for other 
disorders like Parkinson’s disease which affects dopaminergic transmission. 
2.3.4.2.1 Schizophrenia 
TAAR genes are tightly clustered on human chromosome 6q23.2 (Borowsky et al., 2001) 
a site which is close to the schizophrenia susceptibility locus SCZD5 (Duan et al., 2004). 
PE increases have been suggested to cause schizophrenia-like episodes (Davis et al., 
1991; Kitamura et al., 2008). Sensorimotor gating deficits are seen in schizophrenia 
(Quednow et al., 2008; Moriwaki et al., 2009). In animal models prepulse inhibition of 
startle is an indicator of sensorimotor gating deficits (Braff et al., 1978). Prepulse 
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inhibition is a neurological phenomenon in which a weaker prestimulus (prepulse) 
inhibits the reaction to a subsequent strong startling stimulus (pulse). The reduction of the 
amplitude of startle reflects the ability of the nervous system to temporarily adapt to a 
strong sensory stimulus when a preceding weaker signal is given. TAAR1 KO mice show 
deficits in prepulse inhibition (Wolinsky et al., 2007) and thus were proposed as a new 
model for schizophrenia.  
Schizophrenia patients also show an enhanced sensitivity to amphetamines (Breier, 1997; 
Laruelle et al.,1999) and an increase in the high affinity state of D2 receptors is seen 
(Corripio et al., 2006; Hirvonen et al., 2005). As described above amphetamines and D2-
receptors are both suggested to interact with TAAR1 and thus an important role may be 
played by TAAR in the pathophysiology of schizophrenia. Olfactory deficiencies are 
often seen during the symptomatic phases of schizophrenia (Hurwitz et al., 1988; Kopala 
et al., 1989; Serby et al., 1990; Warner et al., 1990; Seidman et al., 1991; Kopala et al., 
1992;  Wu et al., 1993; Kopala et al., 1994; Houlihan et al., 1994; Malspina et al., 1994; 
Kopala et al., 1995;  Brewer et al., 1996). TAAR are now known to be olfactory receptors 
(Liberles and Buck, 2006) and thus TAAR could be a possible common molecular 
substrate for psychiatric and sensory symptoms associated with schizophrenia. 
2.3.4.2.2 Depression 
Depression is thought to be caused by a deficiency of biogenic amine neurotransmission 
(Schildkraut, 1967; Lapin, 1969; Sandler, 1980; Davis and Boulton, 1994; Sabelli, 1996). 
Trace amines regulate neurotransmission (see Section 2.3.2) and therefore may play a 
role in depression. Clinically, decreased trace amine levels are suggested to correlate with 
 21 
 
depressive symptomatology (Sandler, 1980; Davis and Boulton, 1994). Trace amines like 
PE and its precursor L-phenylalanine can improve the affective state of depressed 
individuals (Sabelli, 1996). Antidepressant drugs interact with the re-uptake proteins and 
MAO (Jarema et al., 2011). TAAR regulate re-uptake proteins (see Section 2.3), and 
MAO inhibitors cause increases in trace amine levels. Thus a role of trace amine systems 
in mood control is possible. 
2.3.4.2.3 Parkinson’s Disease 
Parkinson’s disease is caused by degeneration of the dopaminergic neurons in the 
substantia nigra (Dauer and Przedborski, 2003; Phani et al., 2012), which leads to a 
deficiency of dopamine (DA). Thus levodopa (3,4-dihydroxy-L-phenylalanine), the 
immediate precursor of DA, is used as a treatment to alleviate the symptoms of the 
disease (Katzenschlager and Lees, 2002). Continuous treatment with L-dopa has been 
questioned as it leads to other effects like dyskinesia (Cenci et al., 2009; Onofrj et al., 
2009) and the ‘On-Off’ phenomenon (Nutt et al., 1984; Nutt, 1987; Menza et al., 1990). 
This is an increase in refractoriness to L-dopa's ability to control the smooth skeletal 
muscle movement in Parkinson's disease, where periods of excess abnormal movements 
alternate with periods of prolonged immobility or freezing, or symptom control followed 
by loss of control in response to L-dopa. Trace amines increase dopaminergic 
transmission, therefore can act as a novel therapeutic target. AADC is responsible for the 
conversion of externally administered L-dopa to DA. The level of trace amines also 
depends on the activity of AADC. AADC activity is altered depending on the stimulation 
of DA receptors (Rossetti et al., 1990; Hadjiconstantinou et al., 1993; Zhu et al., 1993). 
AADC may act as a rate limiting enzyme in the conversion of L-dopa to DA in 
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Parkinson’s disease due to the large loss of AADC protein associated with degeneration. 
Administered L-dopa is converted to DA which in turn stimulates DA receptors and thus 
symptoms are controlled. However the increase in DA receptor stimulation causes less 
AADC activity so less conversion of L-dopa to DA and less DA receptor stimulation and 
loss of symptom control. AADC activity now starts to increase again due to decreased 
receptor activation and again conversion of L-dopa to DA and again control of 
symptoms. TAAR ligands which regulate DA receptor sensitivity may help control such 
“on-off” symptoms.  
2.4  MEMBRANE PERMEABILITY OF NEURONAL MONOAMINES 
 
In general trace amines do not appear to be actively stored in synaptic vesicles (Wu and 
Boulton, 1975; Philips and Boulton, 1979; Durden and Philips, 1980) although there may 
be both vesicular and non-vesicular pools of p-tyramine (Dyck, 1989). Consistent with 
this general lack of vesicle storage, trace amines also do not appear to be released in an 
activity dependent manner (Dyck et al., 1983). Since they are also predicted to be more 
lipophilic than the monoamine neurotransmitters (Oldendorf et al., 1971; Blakeley and 
Nicol, 1978; Mack and Bonisch, 1979) it has been assumed that trace amines readily 
diffuse across neuronal membranes (Berry, 2004). Consistent with this, Tchercansky et 
al., (1994) studied the transfer of tyramine across rat intestinal membrane and concluded 
it to be via simple diffusion. In contrast, Blakeley and Nicol (1978) concluded tyramine 
entry into erythrocytes occurred by facilitated diffusion. In brain slices, trace amine 
membrane passage was concluded to be most consistent with simple diffusion (Dyck et 
al., 1983, Dyck, 1989). Recent computer simulation studies, however, suggested a high 
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energy barrier for tyramine passage across a lipid bilayer (Berry et al., 2011) raising the 
possibility that the passage of trace amines is not merely passive.  
In biological systems there are mainly two types of carrier mediated transport processes 
that are prevalent, facilitated diffusion and active transport. It is well known that many of 
the nutrients and chemical messengers in the body are transported using the two 
mechanisms. Transporters are present in all organs of the body. Thus due to the presence 
of transporters in the cells of these organs, homeostasis is maintained via exchange of 
chemicals needed for normal functioning. Transport of materials needs to occur in two 
directions, with distinct processes being present for the release of molecules from cells 
and for the entry of metabolites or their pre-cursors. The following sections will focus on 
these two processes as they relate to events at the synaptic cleft, which is the major site of 
action of the trace amines. 
2.4.1 Release mechanisms  
The release mechanism of neuronal monoamine neurotransmitters involves the fusion of 
vesicles filled with monoamine neurotransmitters with the plasma membrane through the 
process of exocytosis (Burger and Schafer, 1998; Ales et al., 1998). This requires 
adenosine 5′ triphosphate (ATP) for initial priming of the apparatus and then the release 
is triggered by calcium whose cytoplasmic levels rise in response to membrane 
depolarization. In the case of trace amines the release is somewhat different as they do 
not appear to be stored in vesicles (Juorio et al., 1988) and K
+
-induced depolarization 
does not increase trace amine release (Dyck, 1989). In contrast, veratridine-induced 
depolarization of brain slices did increase tyramine release (Dyck, 1989), and on this 
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basis it was suggested that multiple synaptic pools of tyramine may exist, with a minor, 
veratridine-sensitive pool present. 
2.4.2 Uptake processes 
Synaptic cleft monoamine neurotransmitters are taken up back into the synaptic terminals 
by two active mechanisms referred to as uptake 1 and uptake 2. Uptake 1 relates to re-
uptake and storage of monoamines in synaptic vesicles for re-use whereas Uptake 2 
relates to the re-uptake and catabolism of monoamines (Lightman and Iversen, 1969). 
Uptake 1 depends on three conditions (Iversen, 1973):  i] absence of bulky N-substituent 
group, ii] absence of methoxyl groups on the aromatic ring, and iii] presence of at least 
one phenolic hydroxyl group (Iversen, 1971). The re-uptake of synaptic monoamines is 
mediated through various transporters as described below. 
The first monoamine transporter identified was the noradrenaline transporter (NAT) 
(Hertting and Axelrod, 1961) which was shown to play a role in the re-uptake mechanism 
into neurons. This was followed by the discovery of dopamine transporter (DAT) and 
serotonin transporter (SERT) (Iverson, 1971). These three transporters are important in 
the mechanism of psychostimulants and antidepressants, as well as in the physiological 
control of synaptic neurotransmitter levels (Barker and Blakley, 1995; Amara and 
Sonders, 1998; Miller et al., 1999). While the transporters show selectivity toward their 
preferred substrate, they also non-specifically transport a variety of compounds, including 
other neurotransmitter amines when their levels are elevated above physiological values 
(Giros et al., 1994).  
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DAT, NET and SERT are located on the pre-synaptic plasma membrane of neuronal 
terminals where they act to pump neurotransmitter out of the synapse back in to the pre-
synaptic terminal (Torres et al., 2003). They have also been identified in the cell 
membranes of various organs such as the stomach, kidney, platelets and adrenal glands 
(Talvenheimo and Rudnick, 1980; Wade et al., 1996; Eisenhofer, 2001). All three 
transporters are dependent on a Na
+
 concentration gradient, which is ultimately 
maintained by the plasma membrane Na
+
/K
+
-ATPase (Rudnick and Clark, 1993; Gu et 
al., 1994), with Na
+
 and Cl
-
 being co-transported with the monoamines (Torres et al., 
2003). Cocaine acts as an inhibitor of monoamine transporters with moderate selectivity 
for DAT (Harris and Baldessarini, 1973; Heikkila et al., 1975; Kuhar et al., 1991) while 
amphetamine acts as a substrate of all the transporters, with little selectivity between the 
three (Torres et al., 2003). Amphetamines also cause the transporters to ‘invert’ and 
pump substrate amines out of the neuron into the synaptic cleft (Fleckenstein et al., 
2007). As such a number of drugs of abuse can increase the synaptic monoamine levels 
through interaction with membrane transporters (Torres et al., 2003), resulting in 
inhibition of re-uptake and stimulation of efflux.  
Trace amines are structurally related to amphetamine and are thus able to interact in a 
similar way with the monoamine transporters. PE, like amphetamine, can inhibit the 
uptake of DA, NA and 5-HT (Dyck et al., 1983). Amphetamine and PE are shown to 
increase DA synaptic levels through its interaction with DAT and vesicular storage 
transporters (Parker and Cubeddu, 1988). An inhibition of DA uptake by PE with an IC50 
of 4.5 µM has been described (Raiteri et al., 1977), however, this value is not 
physiologically relevant. Similarly an inhibition of NA uptake by PE has been described 
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with an IC50 of 0.7 µM (Raiteri et al., 1977).  PE-induced inhibition of 5-HT uptake is 
less potent with an IC50 of 89.5 µM (Raiteri et al., 1977). Similarly, tyramine also inhibits 
the uptake for DA, NA and 5-HT with IC50 values of 2.5 µM, 0.3 µM and 9 µM (Raiteri 
et al., 1977). Octopamine is in general less potent with IC50 values at the DA, NA and 5-
HT transporters of 15.7 µM, 2 µM and 64.1 µM (Raiteri et al., 1977). A number of TRYP 
and amphetamine derivatives such as MDMA have been shown to interact with SERT 
with affinities ranging from 0.1 µM to 100 µM (Horn, 1973; Baumgarten et al., 1975; 
Horn, 1978; Rudnick and Wall, 1992; Hilber et al., 2005). 
Separate transporter proteins are responsible for the loading of neuronal monoamines into 
synaptic vesicles. Vesicular amine transporter (VAT) includes the Vesicular 
acetylcholine transporter (VAChT) and the vesicular monoamine transporter (VMAT) 
which has two isoforms VMAT1 and VMAT2 (Eiden et al., 2004).  VMAT transports 
monoamines like DA, serotonin, noradrenaline and histamine from cytoplasm into 
storage vesicles. Of the two isoforms, VMAT2 is the only vesicular monoamine 
transporter expressed in the CNS neurons (Eiden and Weihe, 2011). The transport 
mechanism is based on a proton gradient where the ratio is one amine into the vesicle for 
two protons leaving the vesicle (Eiden et al., 2004). Endogenous trace amines such as PE, 
tyramine and T1AM have been identified to be substrates for VMAT2 (Borowsky et al., 
2001). Tyramine shows a similar affinity for VMAT 2 as DA with Km values of 0.82 µM 
(DA) and 0.20 µM for tyramine (Partilla et al., 2006). In addition amphetamines interact 
with VMAT2 in a similar manner to that seen with DAT (Fleckenstein et al., 2007) while 
cocaine does not appear to interact directly with VMAT2 (Brown et al., 2001). 
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A large number of organic cation transporters are also present in most cell membranes 
that trace amines could conceivably interact with by virtue of their charged amine 
component. These transporters belong to a number of different families and are 
responsible for transporting various biologically important organic cations and amino 
acids across cellular membranes with varying degrees of specificity (Koepsell et al., 
2003). For example the SLC-6 sub-family transports a variety of monoamines in a Na
+
 
and Cl
-
 dependent manner (Koepsell et al., 2003), while SLC-5 serves as a choline 
transporter, SLC-19 as a thiamine transporter and SLC-22 a general organic cation 
transporter (Koepsell et al., 2003).  PE membrane transport has been reported to be 
independent of all organic cation transporters so far investigated (Fischer et al., 2010) 
while tyramine can act as a substrate for SLC22 (Iseki et al., 1993; Takahashi et al., 1993; 
Breidert et al., 1998) at 100nM. Although T1AM membrane transport has characteristics 
suggesting it is transporter mediated this did not appear to be via any characterized 
organic cation transporters (Ianculescu et al., 2009). 
2.4.3 Methods for studying membrane passage  
Non-cell based model systems have been extensively used for the prediction of 
membrane passage in the absence of transporter proteins. Historically this has often relied 
on simple polarity based predictions of the distribution of compounds of interest between 
polar and non-polar solvents. In addition, several more refined systems that utilize 
artificial membrane systems have been described. 
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2.4.3.1   Polarity-based predictions  
Partition coefficient (log P) values are the ratio of the distribution of a compound of 
interest in octanol to the distribution in water. Log P values have been widely used to 
predict membrane permeability as it defines the lipophilicity of the drugs and is an 
important tool for prediction of in vivo absorption (Buchwald and Bodor, 1998; Avdeef, 
2001). The major disadvantage is that log P does not provide an accurate measurement of 
the lipophilicity of ionizable compounds under physiological conditions as it describes 
the partition coefficient of molecules in non-buffered solutions. However, many 
thousands of compounds have been studied and data correlated to in vivo membrane 
passage. On this basis a number of on-line software tools have been developed to allow 
the prediction of log P scores (http://www.vcclab.org/lab/alogps; 
http://www.acdlabs.com/resources/freeware/chemsketch/logp; 
http://www.chemdbsoft.com/Physical-Property-Prediction.php).  
Topological polar surface area (TPSA) scores are proposed to provide a superior 
prediction of drug transport properties based on the summation of surface contributions 
of polar fragments or atoms (Ertl et al., 2000). Again freely available on-line software 
(http://www.molinspiration.com) is available for the prediction of TPSA scores. 
2.4.3.2 Artificial membrane based systems 
Immobilized artificial membrane chromatography has been used as an in vitro screening 
technique for predicting drug membrane permeability (Pidgeon et al., 1995). Immobilized 
membranes consist of phosphatidylcholine residues which are covalently bound to silica 
propylamine HPLC beads with on column retention time taken as a measure of 
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membrane permeability (Thurnhofer et al., 1991; Liu et al., 1995). Large volume 
screening of drugs is theoretically possible. However, it is limited by the need to detect 
each compound of interest. As such, in order for this to be of general use it requires a 
generally available analytical technique that exhibits a general and sensitive response 
profile to a wide variety of chemical families. In reality this necessitates the use of mass 
spectrometer detectors. Further, while the system allows relative permeabilities to be 
determined it does not readily provide parameters such as lipid bilayer permeability 
(and/or diffusion) coefficients and diffusion half-live across a lipid bilayer. 
Parallel artificial membrane permeability assays (PAMPA) have also been used to predict 
the permeability through lipid membranes. Here transport across multi-well plate inserts 
consisting of a hydrophobic membrane impregnated with egg lecithin are determined 
(Kansy et al., 1998). Again this has a high throughput capacity to screen large number of 
drugs while at the same time giving information regarding the lipophilicity, ionization 
and the solubility status of compounds (Kansy et al., 1998). It is limited by the necessity 
to perform end-point analytical detection for each compound of interest at a variety of 
time points. Again, for general, sensitive detection, this most often requires mass 
spectrometric facilities. Further, it is not readily modified to a continuous monitoring 
protocol. 
Fluorosomes® are phospholipid vesicles containing a trapped fluorescent dye (Melchior, 
2002). The entry of any compound of interest into these vesicles is detected by the 
quenching of the probe fluorescence. The only requirement is the compound of interest 
should quench fluorescence of the probe and the availability of a fluorescence 
spectrometer. This system has been proposed to be useful for the detection of the passage 
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of drugs across lipid bilayer membranes (Melchior, 2002), but has not been widely 
reported in the literature. 
2.4.3.3 Cell culture  
While the above techniques can provide information with respect to the ability of 
compounds to passively cross lipid bilayers, they provide no information about the 
passage across membranes under physiological conditions where active transport 
processes are also present. To obtain such information cell-based assays must be 
conducted. Initial screening of compounds is often done with one of two cell culture 
systems, Caco-2 or MDCK cells. 
Caco-2 cell culture is a proven method that is widely used for membrane permeability 
studies (Artursson, 1990; Artursson et al., 1996; Hidalgo, 1996; Delie and Rubas, 1997). 
Caco-2 cells are human epithelial colorectal adenocarcinoma cells and are particularly 
useful for predicting the intestinal absorption of compounds of interest following 
ingestion. Since trace amines are found in a number of foodstuffs, it was of interest to 
determine their ability to cross Caco-2 cell membranes. The major disadvantage is the 
time required for monolayer formation is 21 days, a low throughput and sensitivity to the 
expression levels of active transporter systems which can lead to incorrect predictions of 
membrane permeability (Chong et al., 1996).  
MDCK (Madin-Darby canine kidney) cells are an alternative cell-based system used to 
assess drug permeability (Irvine et al., 1999). These also form tight junctions (Misfeldt et 
al., 1976; Cereijido et al., 1978) and have been used as a model to assess drug transport 
(Cho et al., 1990; Cho et al., 1996). The major advantage over Caco-2 cells is that 
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MDCK cells grow faster giving a higher throughput as it requires 3 days to form a 
monolayer as compared to 21 days taken by Caco-2. 
2.4.3.4  Synaptosomes  
Synaptosomes are nerve cell endings which can be readily prepared from homogenized 
rat brain (Booth and Clark, 1978; Dodd et al., 1981). They are used to study the transport 
across neuronal membranes, and may have more relevance to trace amines than the above 
described cell culture methods. Synaptosomes retain all the necessary components 
required for neurotransmission which includes storage and release processes (Whittaker, 
1993). The calcium internal resting concentrations (Verhage et al., 1988) as well as 
normal membrane potential regulated by a Na
+
/K
+
-ATPase is maintained which together 
bring about the release of neurotransmitters (Verhage et al., 1991). Hence, synaptosomes 
are a useful model system for the study of membrane permeability of neurally active 
compounds (Breukel et al., 1997).  
2.5 AIMS AND HYPOTHESIS  
 
The trace amines were thought to diffuse across biological membranes easily with little 
energy barrier present. Recent computer simulation studies suggest that other 
mechanisms might exist (Berry et al., 2011) and that a significant energy barrier might be 
involved. The lipid bilayer permeability of trace amines has not previously been 
systematically studied in the absence of membrane transporters. Since membrane passage 
is required for post-synaptic effects, the nature of passage across membranes by trace 
amines will be directly measured. The lack of vesicular storage and depolarization-
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induced release of trace amines previously reported suggests that trace amines may use 
different processes for membrane passage than neurotransmitters. Therefore, the 
membrane permeability of trace amines in presence and absence of transporters will be 
compared to the corresponding neurotransmitters. 
2.5.1 Hypothesis 
Trace amines membrane transport is by passive diffusion. The major objectives are to a) 
compare the ability of trace amines to diffuse across lipid bilayer membranes in the 
absence of membrane proteins to that of the structurally related monoamine 
neurotransmitters and b) examine the effect of the presence of membrane proteins in 
physiological membranes on the lipid bilayer permeability of a trace amine and its 
structurally related monoamine neurotransmitter. 
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3 MATERIAL AND METHODS  
3.1 FLUOROSOMES 
 
Membrane permeability of trace amines was measured using Fluorosomes® (GL 
Synthesis Inc. Worcester, MA). These are phosphotidylcholine vescicles with covalently 
trapped fluorescent dye. Studies were conducted using a SpectraMax M5 plate reader 
(Molecular Devices, Sunnyvale, CA) operating in kinetic mode and using black walled 
96-well plates (Corning, Canada). The Fluorosomes
®
 kit consists of a proprietary 
fluorophore, proprietary H. buffer and a standard solution of amiloride. Drug solutions 
were prepared in 18 MΩ water. All assays were conducted at 37°C, pH 7.4. Tyramine 
and octopamine were used at 46.9 mM, PE was used at 85 mM, DA and noradrenaline at 
93.8 mM, TRYP 9.4 mM and 5-HT 2.3 mM. Preliminary studies were performed to 
determine whether individual compounds quenched fluorescence and what concentration 
of the individual compound would be required to produce quenching using the 
fluorophore alone. Fluorescence was measured with an excitation wavelength of 494 nm 
and emission at 523 nm. To determine whether quenching occurs with each compound, 
the fluorophore was added to individual wells of black walled 96-well plates. First 15 L 
of fluorosome probe was added to 145 L of buffer. Fluorescence was followed for 25 
seconds after which 15 L of compound of interest was added and fluorescence followed 
for a further 25 seconds. As per manufacturers instructions, only compounds causing a 
greater than 10% decrease in fluorescence were used in subsequent assays. 
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To determine membrane permeability 15 L of Fluorosome solution was added to 145 
L of buffer and baseline fluorescence determined for 50 seconds at 1 second intervals. 
Fluorescence was determined for another 350 seconds at 2 second intervals after addition 
of 15 L of compound of interest. Post-addition data was fit to a first-order decay 
function using GraphPad Prism 5.0 (La Jolla, CA). Equation parameters were then 
entered into the manufacturer’s provided software algorithm to obtain permeability 
coefficients and diffusion half-lives. The mean +/- SEM of 6-8 independent experiments, 
each conducted on a different day, was determined for each compound. Differences 
between the corresponding neurotransmitter and trace amines were determined using an 
unpaired t-test with Welch correction using GraphPad Instat 3.10 software (La Jolla, CA) 
and statistical significance taken at a level of p < 0.05. On each day of assay, the 
permeability coefficient and diffusion half-life of the manufacturer’s positive control 
(amiloride) was determined and confirmed to be within 10-15% of accepted values.  
3.2 PARTITION COEFFICIENT, TOPOLOGICAL POLAR 
SURFACE AREA AND DISTRIBUTION COEFFICIENTS. 
 
Log P values and TPSA values were obtained from online software 
(www.molinspiration.com). Although log P values have been used to predict membrane 
transport, under physiological conditions trace amines and neurotransmitters are in a 
buffered solution. Thus a distribution coefficient (log D7.4) was also determined for 
compounds distribution between octanol and phosphate-buffered saline (PBS; 50 mM, 
pH 7.4).  
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A modification of the shake flask (OECD guideline section 1) method was used to 
determine log D7.4 values. Compounds were dissolved in 2 mL octanol and then 2 mL 
50mM PBS (pH = 7.4) was added in 15 mL Falcon tubes (VWR International, 
Mississauga, ON). The solution was incubated at 37°C for 6 hrs with constant shaking. 
The octanol and the PBS layers were separated and the concentration of compound in 
each phase determined by measuring absorbance at 280 nm using an Agilent 8453 UV 
diode spectrophotometer (Agilent, Brockville, Ontario) (single beam) with collimator and 
comparison to standard curves prepared the day of each experiment. Quartz cuvettes 
(Hellma Quartz Semi micro Cells, 10 mm path length rectangular cells) were used for all 
determinations. Preliminary experiments determined the solubility of each compound in 
the two phases and the linear range for determination of standard curves. Suitable starting 
concentrations based on the anticipated distribution for each compound and linear range 
of each standard curve, were determined to be 600 M for DA, tyramine, octopamine and 
TRYP, and 1 mM for noradrenaline.  
3.2.1 Data Analysis 
Log D7.4 data represent mean ± SEM of 9-14 independent experiments. Data for a trace 
amine and its corresponding neurotransmitter were compared by unpaired t-test with 
Welch correction for unequal standard deviations. Significance was taken at a level of 
P<0.05.  
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3.3 Caco-2 CELL CULTURE 
3.3.1 Materials 
DMEM High with sodium pyruvate, T-75 Flasks and HBSS were obtained from Fisher 
Scientific (Ottawa, Ontario); Fetal Bovine Serum, MEM-NEAA, Transwell CL 6.5 mm 
plates, Versene, and Trypan blue were obtained from Gibco (Burlington, Ontario); 
Trypsin 2.5%, pargyline, sodium diethyldithiocarbamate trihydrate, Lucifer yellow and 
HEPES were obtained from Sigma-Aldrich, (Oakville, Ontario); OR-486 was obtained 
from Tocris Bioscience (Ellisville, MO); [
3
H]-tyramine from American Radiochemicals 
Company (St. Louis, MO); and [
3
H]-dopamine from Perkin Elmer (Boston, MA). Caco-
2/TC-7 cells were a kind gift from Dr. Wolfgang Koester, Vaccine and Infectious Disease 
Organization (VIDO), University of Saskatchewan (Saskatoon, SK) having a passage 
number of 40-45. 
3.3.2 Cell Culture 
Caco-2 cells were cultured as previously described (Sun and Pang, 2008). Complete 
media was prepared by adding 50 mL of FBS and 5.5 mL MEM-NEAA to 500 mL of 
DMEM media. Frozen stocks of cells were thawed quickly at 37
o
C and were transferred 
into a centrifuge tube containing 5 mL of complete media. The tube was centrifuged at 
1000 rpm for 5 minutes. The supernatant was discarded and the pellet re-suspended into 
10 mL of fresh media by pipetting up and down several times. A T-75 cell culture flask 
was filled with 15 mL of media and 0.5 mL of cell suspension was added to the T-75 
flask containing the media. Flasks were incubated at 37
o
C in 5% CO2 until cells were 
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confluent. The media was changed every 2-3 days and the confluent cells were then sub-
cultured as described below. 
3.3.2.1 Subculture of Cells 
Media from confluent cells was removed and cells rinsed with 5 mL of Versene. After 
rinsing the flask with Versene, 2 mL Versene was added again and 4-5 drops of 2.5% 
trypsin solution (final concentration of trypsin is 0.5%) was added. The flask was 
incubated at 37
o
C and 5% CO2 for 3-4 minutes and 5 mL of complete media was added to 
stop the reaction. The cell suspension was collected in a centrifuge tube and centrifuged 
at 1000 rpm for 5 minutes. Medium was decanted and cells suspended in 10 mL of 
complete media by pipetting up and down several times. Another T-75 flask containing 
15 mL of complete media was taken and 0.5 mL of the cell suspension was added. 
3.3.2.2 Culture into Transwell® Plates 
Cells, at passage number 40-45, were harvested when they were more than 90% 
confluent as described above. Cell suspension (90 L) was added to 10 L of trypan blue 
solution and cell viability was determined as follows. A Neubar’s chamber was loaded 
with 10 L of mixture. Four quarters containing 16 squares were counted and the average 
was taken. This average was multiplied by 1.11x10
4 
to determine the number of cells per 
mL. The basal compartment of a transwell plate was filled with 600 L of complete 
media. The apical compartment was filled with 200 L of cell suspension containing 
1x10
5 
cells as previously described (Sun and Pang, 2008). The plate was incubated at 
37
o
C and 5% CO2 and the media was changed every alternate day for 21 days. On the 21
st
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day Trans-epithelial electric resistance (TEER) values were measured as described 
below.  
3.3.2.3 Trans-epithelial Electrical Resistance  
TEER electrodes (Millipore, Billerica, MA) were dipped into 70% alcohol for 2 minutes 
and then transferred into media for 10-15 minutes. In the voltage mode, the voltage was 
adjusted to zero. Similarly in resistance mode, the resistance was adjusted to zero. 
Electrodes were inserted into the apical and basal sides of the transwell plate and the 
resistance measured. TEER values between 500-900Ω indicates integrity of the 
monolayer. 
3.3.2.4 Lucifer yellow (LY) 
Post-assay Lucifer yellow (LY) rejection rate was measured to assess monolayer integrity 
at the end of the permeability assay. Caco-2 monolayers were washed three times with 
the transport medium. After a 30-min equilibration period, transport media on the apical 
side was replaced with 0.2 mL of Lucifer yellow solution (100 µg/mL). Blank solution 
(600 µL, in this case HBSS + inhibitors) was added to the top row wells of the plate and 
bottom row wells consist of 400 µL blank plus 200 µL Lucifer yellow and the plate was  
incubated for 1 h at 37°C under 5% O2, 95% CO2 and 95% humidity for 1 h. Lucifer 
Yellow fluorescence emission (excitation wavelength = 485 nm, emission wavelength = 
535 nm) in the basal compartment was read using a Biotek Synergy HT microplate reader 
(Fisher Scientific, Nepean, ON, Canada) and the concentration determined by 
comparison of fluorescence emission of basal compartment against standards after 
background subtraction. Percent Lucifer yellow rejection was calculated from the 
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fluorescence values and Lucifer yellow rejection was calculated using the following 
equation. 
LY rejection = 100 - % LY rejection 
3.3.2.5 Permeability Experiment 
Modified Hank’s balanced salt solution (HBSS) consists of HBSS (CaCl2.H2O 186 
mg/mL, KCl 400 mg/mL, KH2PO4 60mg/mL, MgSO4.7H2O 200 mg/mL, NaCl 8 mg/mL 
NaHCO3 350 mg/mL, Na2HPO4.7H2O 90 mg/mL and glucose 1000 mg/mL) with 20 mM 
HEPES, pH 7.4.  All compounds were prepared in this modified HBSS. All solutions also 
contained three inhibitors of monoamine metabolism. Pargyline was used at 10 M 
concentration to inhibit MAO-A and MAO-B (Murphy et al., 1998). OR-486, which is a 
COMT inhibitor, was used at 2.5 mM concentration (Nissinen et al., 1988). Sodium 
diethyldithiocarbamate trihydrate was used at 100 M to inhibit dopamine-β-hydroxylase 
(Szmigielski, 1975). The monolayers were rinsed three times with 200 L of modified 
HBSS on the apical side and 600 L on the basal side. [3H]-Tyramine and [3H]-dopamine 
additions were either done on the apical (upper chamber) or the basal (lower chamber) 
side. For apical side addition, after washing the cells, the apical side was filled with 190 
L of modified HBSS containing the inhibitors. The basal side received 600 L of 
modified HBSS with inhibitors. Similarly for the basal side addition, after washing the 
cells, the apical end was filled with 200 L of modified HBSS with inhibitors and the 
basal side was filled with 590 L of modified HBSS with inhibitors. [3H]-Tyramine or 
[
3
H]-dopamine was added to either the apical or basal sides in 10 L volume to give final 
concentration of 100 nM for tyramine and 10 for DA. Cells were incubated for 
 40 
 
varying time periods (5, 10, 20, 30, 45 and 60 minutes) at 37°C in 5% CO2 atmosphere 
following the addition of radiolabelled compound. After incubation, the apical and the 
basal solutions were transferred into scintillation vials. Fresh modified HBSS containing 
inhibitors, 200 µL for the apical side and 600 L for the basal side, was added to each 
side of the insert. The apical wash solution was transferred to a separate scintillation vial 
and replaced with Lucifer yellow solution (100 µg/mL in HBSS). After 1 hour of 
incubation at 37°C, inserts were removed, and the plate was taken for fluorescence 
reading at an excitation wavelength of 485 nm and emission wavelength of 535 nm. The 
insert solution was combined with the apical wash solution in a scintillation vial and 
replaced with NP-40 cell lysis buffer (20 mM Tris (pH 8.0), 137 mM NaCl, 10% (v/v) 
glycerol, 1% (v/v) NP-40, 2 mM EDTA) in another 24-well plate and incubated for 30 
minutes at 37°C. After incubation this was combined in the scintillation vial with the 
Lucifer yellow and wash solutions.  
Ten mL of scintillation cocktail (Ready safe®) was added to each scintillation vial and 
after at least 4 hours the vials counted for tritium using a Beckman beta counter 
(Mississauga, Ontario) having a counting efficiency of 0.6. The amount of radioactivity 
present in the apical solution, basal solution and cells at each time point was converted to 
moles of tyramine or DA by comparison to a standard curve. 
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3.4 SYNAPTOSOMES        
3.4.1 Preparation of Synaptosomes  
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane 
animal use. Male Wistar rats (200-250g) were deeply anesthetized with urethane (1 g/kg 
i.p.). They were then decapitated and the brain was dissected out and kept in 0.9% ice 
cold NaCl. Synaptosomes were prepared as described by Miller et al., (2005). The brain 
was diced on ice and homogenized using a Teflon-coated manual homogenizer in 10 
volumes of 35 mM sucrose solution. Then, the homogenate was centrifuged at 1000g for 
10 minutes at 4°C. The supernatant was collected and the pellet discarded. The 
supernatant was centrifuged again at 10,000g for 20 minutes at 4°C. The supernatant was 
discarded and the pellet resuspended in 2 mL of ice-cold assay buffer. The assay buffer 
consists of 25 mM HEPES, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
10 µM pargyline, 100 µM diethyldithiocarbamate, 2.5 µM OR-486, 2 µg/mL glucose, 0.2 
µg/mL ascorbic acid and pH at 7.5. 
3.4.2 Uptake Assay 
Eppendorf tubes (1.5 mL) were filled with 50 µL synaptosomes and either 10 µL of [
3
H]-
dopamine (specific activity = 38 Ci/mmol) or [
3
H]-tyramine (specific activity = 40 
Ci/mmol). Tyramine was added at a concentration of 100 nM and DA was added at a 
concentration of 10 µM. The tubes were then incubated for 1, 2, 3, 4, 5, 10, 20 and 30 
minutes in a water bath at 37°C. The reaction was stopped by adding 1 mL ice-cold 
buffer. The tubes were then centrifuged at 10,000g for 3 minutes at 4°C. The supernatant 
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was collected in scintillation vials for counting for radioactivity. The pellet was re-
suspended in 0.5 mL NP-40 lysis buffer and incubated at 37°C for 30 minutes. The lysis 
solutions were transferred to scintillation vials for counting as previously described. 
3.4.3 Release Assay 
Eppendorf tubes with 50 µL of synaptosomes were incubated with 10 µL of radiolabelled 
tyramine or DA for 10 minutes and the reaction was stopped with 1 mL ice-cold assay 
buffer as described above. The tubes were then centrifuged at 10,000g at 4°C for 3 
minutes. The supernatant was discarded and the pellets were re-suspended in 0.5 mL of 
ice-cold buffer and all the tubes centrifuged again. Supernatants were discarded and one 
of the pellets, time 0 minute tube was re-suspended in 0.5 mL buffer and immediately 
centrifuged as described above. The supernatant was collected and the pellet was 
resuspended in lysis buffer and incubated for 30 minutes and then counted for 
radioactivity. The remaining pellets were resuspended in 0.5 mL incubation buffer and 
incubated for 1, 2, 3, 4, 5, 10, 20 and 30 minutes at 37°C. After incubation, tubes were 
centrifuged at 10,000g for 3 minutes at 4°C and supernatants collected in separate 
scintillation vials and pellets kept on ice. All of the pellets were then re-suspended with 
0.5 mL lysis buffer and incubated for 30 minutes at 37°C and then collected in separate 
vials for counting. 
3.4.4 Release in Depolarized Synaptosomes Assay 
The studies were conducted as above with the exception that the pellets were suspended 
in a high potassium (25 mM) assay buffer for the release assay. 
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3.4.5 Protein Assay  
Bradford’s protein assay kit (Bio-Rad, Hercules, CA) was used in which standard serum 
albumin was used to make different concentration of standards from 1000 µg to 50 µg 
protein. All assays were conducted using 96-well assay plates.  For determination of the 
protein content of synaptosomes, 5 µL of synaptosome preparation was used and 200 µL 
of the Bradford reagent added and the plates incubated in the dark for 15 minutes at room 
temperature. Absorbence was measured at 595 nm wavelength. The protein concentration 
in each sample was calculated from the standard curve. All assays were conducted in 
triplicate and the average taken for each sample. 
3.4.6. Data Analysis 
The uptake studies were compared by plotting the amount of compound of interest in 
supernatant and synaptosomes against time. For the release data the amount of compound 
released was plotted against time and a one-phase decay function was applied using 
Graphpad Prism. Rate constants and half-lives were obtained from the line fit parameters. 
Rate constants were statistically compared by an F-test using GraphPad Prism and 
significance taken at P<0.05. 
 44 
 
4 RESULTS 
4.1 FLUOROSOMES 
 
Preliminary studies determined the concentration of the compounds required to quench 
the fluorescence of the probe (Figures 3 and 4). PE was found not to quench the 
fluorescence of free probe at any concentration used (Figure 5) and, hence, could not be 
investigated further. Compounds showing greater than 10% quenching of the free 
fluorophore were investigated further. Representative graphs of the quenching of 
fluorosome fluorescence by amiloride, DA and tyramine, NA and octopamine, and for 5-
HT and TRYP are shown in figures 7-9, respectively.  
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Figure 3 : Effect of 9.4 mM TRYP  on free fluorosome probe fluorescence. 
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Figure 4 : Effect of 6.25 mM tyramine on free fluorosome probe fluorescence. 
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Figure 5: Effect of 85 mM PE on free fluorosome probe fluorescence. 
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Figure 6: Effect of amiloride on fluorosome fluorescence.  
On addition of amiloride the compound quenched fluorescence as seen as a drop from baseline 
depicted by the curve over 400 seconds. 
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Figure 7: Quenching of Fluorosome fluorescence following addition of 93.8 mM 
dopamine and 46.9 mM tyramine.  
 
DA showed a slower quenching of fluorescence from the baseline as compared to tyramine which 
quenched relatively fast. 
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Figure 8: Quenching of Fluorosome fluorescence following addition of 93.8 mM NA and 
46.9 mM OCT.  
 
NA and OCT showed almost similar quenching pattern over 400 seconds with no significant 
differences from each other. 
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Figure 9: Quenching of Fluorosome fluorescence following addition of 2.3 mM 5-HT and 
9.4 mM TRYP.  
 
5-HT and TRYP both quenched fluorescence. TRYP quenched almost as soon as it was added as 
compared to a slower quenching shown by 5-HT. 
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The permeability coefficient and the diffusion half-lives obtained for each compound are 
shown in Table 3. A significant (p < 0.01) three-fold reduction in permeability coefficient 
was observed when DA was compared to p-tyramine. Similarly, 5-HT permeability 
coefficient was significantly (p < 0.001) smaller (7 times) than TRYP permeability 
coefficient. Half-lives were correspondingly changed with DA showing a 2.6-fold greater 
half-life than p-tyramine (p < 0.01), and 5-HT a 7-fold greater half-life than TRYP (p < 
0.001). NA permeability coefficient and half-life were not statistically different from 
those of OCT. 
 
Table 3: Biogenic amine permeability coefficient and diffusion half-lives across 
Fluorosome lipid bilayer membranes.  
**
Significantly different at p < 0.01 
***
Significantly different at p < 0.001. Data represent mean ± SEM, n = 6-9. Pairs of compounds 
were compared by unpaired t-test with Welch correction for unequal standard deviations.  
COMPOUNDS PERMEABILITY 
COEFFICIENT 
                  (Å/sec) 
HALF-LIFE (sec) 
DOPAMINE 
TYRAMINE 
7.7 ± 1.2** 
22.6 ± 4.3 
35.9 ± 7.0** 
13.5 ± 4.1 
NORADRENALINE 
OCTOPAMINE 
20.3 ± 3.8 
19.1 ± 2.9 
14.7± 3.4 
12.5 ± 1.7 
5-HT 
TRYPTAMINE 
4.8 ± 0.6*** 
33.2 ± 3.3 
48.2 ± 5.9*** 
6.8 ± 0.7 
AMILORIDE 2.2 ± 0.4 134.1 ± 36.7 
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The permeability coefficient and half-lives of the three trace amines were compared by 
one-way ANOVA revealing a marginally significant (p < 0.05) difference between 
groups in permeability coefficient, but not half-life. Differences between groups were 
tested with a Bonferroni multiple comparisons post-hoc test, with a significant difference 
(p < 0.05) observed between TRYP and OA permeability coefficients. Since the 
permeability coefficients of trace amines in general showed greater values and the 
diffusion half-lives were smaller than the neurotransmitters, all the values were pooled 
together and compared using a Mann-Whitney U-test (Figure 10). Trace amines as a 
group showed statistically (p < 0.0001) greater permeability coefficient and 
correspondingly lower diffusion half-lives than the neurotransmitters. 
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Figure 10: Comparison of pooled neurotransmitter and trace amine membrane 
permeability measures.  
 
Pooled data compared using Mann-Whitney U-test. 
*** Trace amines as a group show statistically (p<0.0001) greater permeability coefficient and 
corresponding lower diffusion half-live than the corresponding neurotransmitters. 
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4.2 PARTITION COEFFICIENT, TOPOLOGICAL POLAR 
SURFACE AREA AND DISTRIBUTION COEFFICIENTS. 
 
Predicted log P and TPSA values were obtained from the molinspiration website 
(http://www.molinspiration.com/cgibin/properties) as a potential predictor of distribution 
between aqueous and lipid phases, and are shown in Table 4. 5-HT log D7.4 value could 
not be determined as 5-HT did not dissolve in octanol at a concentration that could be 
detected by UV spectroscopy. The predicted values from Table 4 were plotted against the 
permeability coefficients determined from Fluorosome studies and examined for signs of 
a relationship (Figure 11). There was no obvious trend observed. 
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Table 4: Comparison of Predicted log P, Predicted TPSA and experimentally determined 
log D7.4 values. 
Log D7.4 data represent mean ± SEM of 9-14 independent experiments. Pairs of log D7.4 data were 
compared by unpaired t-test with Welch correction for unequal standard deviations. ** p<0.001.  
 
 
 
 
 
 
 
 
 Predicted log P Predicted TPSA log D7.4 
Dopamine 
p-Tyramine 
-0.047 
0.442 
66.479 
46.251 
-0.68 ± 0.07 
-0.79 ± 0.03 
Noradrenaline 
p-Octopamine 
-1.038 
-0.549 
86.707 
66.479 
-0.90 ± 0.05 
-0.65 ± 0.04** 
5-HT 
Tryptamine 
0.568 
1.071 
62.042 
41.814 
 
0.21 ± 0.02 
Amiloride -1.244 156.803  
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Figure 11: Relationship of predicted TPSA and log P scores to Fluorosome membrane 
permeability coefficients. 
 
 
 
 
 
 
 
 
 
 
 
 58 
 
Since there was no obvious correlation between either predicted log P or TPSA scores 
and Fluorosome permeability data, the distribution between octanol and a PBS solution 
buffered to physiological pH was determined. Standard curves in octanol and PBS were 
made for each compound by using a wide range of concentrations and measuring their 
absorbance (Figures 12-15). From these data, the distribution of compounds between 
octanol and PBS phases could be determined allowing the calculation of log D7.4 (Table 
4).  Pair-wise comparison was done between DA and tyramine, noradrenaline and 
octopamine of which noradrenaline and octopamine were significantly different 
(p<0.001). TRYP log D7.4 values could not be determined as the compound was not 
sufficiently soluble in octanol and PBS to allow its detection by UV spectroscopy. 
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Figure 12: Representative standard curve of dopamine in PBS.  
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Figure 13: Representative standard curve of dopamine in octanol.  
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Figure 14: Representative standard curve of tyramine in PBS. 
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Figure 15: Representative standard curve of tyramine in octanol 
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Figure 16: Relationship of log D7.4 to Fluorosome membrane permeabilities. 
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The calculated log D7.4 values were also plotted against the permeability coefficient 
values determined from Fluorosome studies as shown in figure 16. This showed more 
evidence of a predictive relationship than was observed with log P and TPSA scores. 
4.3 CELL CULTURE 
 
Caco-2 cell culture was used to determine the permeability of one neurotransmitter [
3
H]-
dopamine and one trace amine [
3
H]-tyramine. These were selected as they were readily 
available and cost effective as compared to others. Tyramine accumulation (~7-8% of 
administered concentration) was approximately twice that of DA (3-4%). From Figures 
17 and 18 it can be seen that equilibration of both tyramine and DA occurred in less than 
10 minutes. Initial studies were conducted with 5-minute sampling with equilibration 
already evident (data not shown). The flux constant could not be determined as 
equilibration occurred at such short time points that precluded accurate sampling. 
Representative standard curves to allow the calculation of tyramine and DA 
concentrations are shown in figures 19 and 20.  
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Figure 17: Permeability of [
3
H]-tyramine in Caco-2 cell culture upon apical and basal 
additions.  
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Figure 18: Permeability of [
3
H]-dopamine in Caco-2 cells following apical and basal 
addition.  
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Figure 19: Standard curve for [
3
H]-tyramine application. 
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Figure 20: Standard curve for [
3
H]-dopamine application  
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4.4 SYNAPTOSOMES 
 
Caco-2 cell culture predicts the intestinal permeability whereas synaptosomes can 
provide a measure of neuronal permeability. Since trace amines are synthesized 
neuronally as well as being ingested in foodstuffs, the uptake and release of [
3
H]-
dopamine and [
3
H]-tyramine were also determined in rat brain synaptosomes. The 
radioactivity from the supernatant and synaptosomes was counted at individual time 
points and the amount of the radioactive drug determined by comparison to standard 
curves. Total protein present in the synaptosome pellets was determined by Bradford’s 
protein assay (Figure 21). The amount of each compound taken up into synaptosomes, 
corrected for total protein present, was plotted against time of incubation (Figure 22 and 
23). Equilibration was reached within 5 minutes for both tyramine (Figure 22) and DA 
(Figure 23), although a trend to a slower equilibration time may have been present for 
DA.  
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Figure 21: Standard curve for protein assay.  
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Figure 22: Uptake of [
3
H]-tyramine in rat brain synaptosomes. 
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Figure 23: Uptake of [
3
H]-dopamine in rat brain synaptosomes. 
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The release of [
3
H]-dopamine and [
3
H]-tyramine was determined following loading of 
synaptosomes with [
3
H]-tyramine and [
3
H]-dopamine for 10 minutes. Release was 
measured at different incubation times under normal and depolarizing conditions (Figure 
24 to 25). The first-order rate constant and the half-lives were calculated by fitting the 
release data to a one-phase exponential decay function (table 5).  
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Figure 24: Release of [
3
H]-tyramine under basal and high K+-induced depolarization 
conditions.  
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Figure 25: [
3
H]-Dopamine release from synaptosomes under basal and high K+-induced 
depolarization conditions.  
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Figure 26: Comparison of the release of [
3
H]-tyramine and [
3
H]-dopamine from 
synaptosomes under basal conditions 
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Figure 27: Comparison of the release of [
3
H]-tyramine and [
3
H]-dopamine from 
synaptosomes following high K
+
-induced depolarization.  
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Table 5: Rate constants and half-lives for [
3
H]-tyramine and [
3
H]-dopamine release under 
various conditions.  
**Tyramine release was significantly (p <0.001) faster than dopamine release. 
# 
Tyramine high K release was significantly slower than tyramine release (p<0.05) 
##
Dopamine release significantly (p < 0.01) slower than dopamine release in high K. 
 
The results were analyzed by fitting a one-phase exponential decay function to the data 
and the resultant curves compared with an F-test. Tyramine release occurred significantly 
(p = 0.0042, F = 8.77) quicker than DA (figure 26). High K+ caused a significant (p = 
0.01, F = 6.95) increase in the rate of DA release and a significant decrease for tyramine 
(p = 0.02, F = 5.86) shown in Figures 25 and 24. There was no significant difference 
between DA and tyramine release under high K
+ 
induced depolarization. 
Tyramine release between 2 and 4 minutes time points under basal and depolarizing 
conditions showed an apparent plateau which was not seen with DA and could suggest 
multiple pools of tyramine release. However, a two-phase exponential curve fit was not 
significantly better than the one-phase curve ( p > 0.05, F = 0.588). 
 K (Rate constant 1/minute) HALF-LIFE (minute) 
TYRAMINE RELEASE 1.064 ± 0.23** 0.65 
TYRAMINE RELEASE 
HIGH K 
0.4109 ± 0.09# 1.69 
DOPAMINE RELEASE 0.3113 ± 0.07## 2.23 
DOPAMINE RELEASE 
HIGH K 
0.70 ± 0.11 0.99 
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Tyramine synaptosome release data and tyramine fluorosome data was compared using 
an F-test. Tyramine membrane passage was significantly faster (F = 13.63, p = 0.0002) in 
Fluorosomes than in synaptosomes. Similarly DA synaptosome data and DA fluorosome 
data was compared and membrane passage in Fluorosomes was again significantly faster 
(F = 56.77 and p = 0.0001).  
 
Table 6: Comparison of the rate constants and half-lives for tyramine and dopamine in 
synaptosome and Fluorosome assay systems.  
** Tyramine synaptosome release was significantly (p < 0.0002) slower than tyramine 
fluorosome entry. 
*** Dopamine synaptosome release was significantly (p < 0.0001) slower than dopamine 
fluorosome entry. 
 K (Rate constant 1/second) HALF-LIFE (seconds) 
Tyramine synaptosome 0.0178 ± 0.0038** 38.9 
Tyramine fluorosome 0.0587 ± 0.0080 13.9 
Dopamine synaptosome 0.0052 ± 0.0013*** 133.6 
Dopamine fluorosome 0.0167 ± 0.0009 35.9 
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5 DISCUSSION 
The trace amines are biogenic amines which are structurally similar to monoamine 
neurotransmitters. The synthesis of trace amines is regulated by AADC (Paterson et al., 
1990) and they alter responses of neurotransmitters (Jones, 1981; Paterson et al., 1990; 
Berry, 1994). In general trace amines do not appear to be actively stored in synaptic 
vesicles (Wu and Boulton, 1975; Philips and Boulton, 1979; Durden and Philips, 1980). 
Consistent with this, trace amines also do not appear to be released in an activity-
dependent manner (Dyck et al., 1983). Since they are also more lipophilic than the 
monoamine neurotransmitters (Oldendorf, 1971; Blakeley and Nicol, 1978; Mack and 
Bonisch, 1979), it has been assumed that trace amines readily diffuse across neuronal 
membranes (Berry, 2004) and furthermore that their release is not via exocytosis. The 
TAARs are GPCRs (Borowski et al., 2001; Buzow et al., 2001), but unlike 
neurotransmitter GPCRs these are thought to be intracellular (Bunzow et al., 2001; 
Lindemann and Hoener, 2005; Xie et al., 2008). Thus, for trace amines to exert post-
synaptic effects at these receptors they have to cross cell membranes.  
Previous studies have suggested that trace amines can cross the lipid cell membrane by 
simple diffusion (Blakeley and Nicol, 1978; Tchercansky et al. 1994). The entry of NA, 
5-HT and tyramine was rapid into erythrocytes and it was concluded that this occurred by 
facilitated diffusion (Blakeley and Nicol, 1978). Tchercansky et al., (1994) examined the 
transfer of tyramine across rat intestinal membranes and concluded that this occurred by 
simple diffusion. Both of these studies, however, used biological membranes with 
transporter proteins present which could complicate determination of permeability 
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coefficients related to simple diffusion. Thus, the current studies provide the first 
systematic examination of membrane permeability of trace amines in both the absence 
and presence of membrane transporters and compare this to that of monoamine 
neurotransmitters. 
Fluorosomes® are phospholipid vesicles containing a trapped fluorescent dye. The entry 
of any compound of interest into these vesicles is detected by the quenching of the 
fluorescence. From table 3 it can be seen that trace amines enter Fluorosomes statistically 
quicker than the corresponding neurotransmitters. The permeability coefficient of 
tyramine was 65% greater than that of DA while TRYP’s permeability coefficient was 
85.5% greater than that of 5-HT. The half-lives for DA and 5HT membrane passage were 
correspondingly greater than those of tyramine and TRYP.  
The average thickness of a cell membrane is 30-60Å (Andersen and Koeppe, 2007). 
Membrane permeabilities for trace amines were between 19 and 33 Å/second suggesting 
that membrane passage by simple diffusion can occur in less than 3 seconds. In contrast, 
neurotransmitter membrane permeabilities were 4 to 20 Å/second suggesting the 
membrane passage by simple diffusion would require up to 10 seconds. These data for 
trace amines are consistent with previous in vivo electrophysiology studies, where 
neurotransmitter modifying effects of trace amines were seen to occur very rapidly (Jones 
and Boulton, 1980; Paterson, 1988; Berry, 2004). PE permeability characteristics could 
not be determined as it did not quench the fluorescence of free fluorosome probe. 
Chemically PE is dehydroxylated tyramine and is therefore expected to be less polar. As 
such it would be expected that this will result in increased lipophilicity and therefore even 
greater membrane permeability than was seen with tyramine. 
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Log P, log D7.4 and TPSA scores were compared to Fluorosome permeability data. There 
was no indication of any trend toward a predictive relationship between membrane 
permeability in the fluorosome assay and either log P or TPSA scores (Figure 11). Log 
D7.4 was expected to be a better indicator of membrane permeability as the pH was 
maintained at physiological pH. When log D7.4 data were compared with permeability 
coefficient values (figure 16) the graph was more suggestive of a possible predictive 
relationship. However, both of these studies evaluated only 6 compounds and far greater 
than 6 values would be required for a full statistical comparison.  
Trace amines have been found in high levels in various foodstuffs, most notably cheese 
(El-zayat and El-Bagoury, 1988; Joosten, 1988a,b; Stratton et al., 1991; Tawfik et al., 
1992), red wine (Ibe et al., 1991; Ancin-Azpilicueta et al., 2008) and chocolates 
(Ziegleder et al., 1992). Such foodstuffs have been implicated in food-induced toxicity, in 
particular food-induced migraine (Hanington, 1967; Vaughan, 1994) and the ‘cheese’-
effect associated with certain antidepressant therapeutics (Blackwell, 1963). As such, it is 
of interest to determine the ability of trace amines to cross intestinal epithelial 
membranes. 
Caco-2 cell culture provided a model of the absorption of the compounds through an 
intestinal membrane. Both tyramine and DA distribution between cellular, apical and 
basal compartments reached equilibrium within 10 minutes, with no evidence of a 
difference between basal and apical additions (Figures 17 and 18). Preliminary studies 
showed that this was also true at 5 minutes. Shorter time points could not be studied as it 
was not physically possible to accurately isolate the three required compartments in such 
short time spans. A different sampling method would be required in order to determine 
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distributions at such short incubation times. As a result of these limitations, rate constants 
and flux values could not be determined in Caco-2 cells. However, it was found that 
tyramine accumulation in the acceptor side (≈ 7-8% of administered) was approximately 
twice that of DA (3-4%) at equilibrium. Such a low fraction of administered 
concentration being accumulated suggested that in the presence of membrane proteins 
both tyramine and DA were either actively pumped out of Caco-2 cells or actively 
prevented from entering. The greater accumulation of tyramine than DA appears 
consistent with the permeability coefficient values from fluorosome data showing 
tyramine to be more permeable than DA (table 3).   
Caco-2 cells express a variety of transporters (Sun and Pang, 2008). These are both 
uptake and efflux transporters and belong to two major super families, one is ATP-
binding ABC transporters and solute carrier (SLC and SLCO) family of transporters 
(Smetanova et al., 2011). Tyramine and DA interact with these transporters at 
concentrations of 100 nM through the organic cation transporters 1 (Iseki et al., 1993; 
Takahashi et al., 1993; Breidert et al., 1998; Koepsell et al., 2003). These are similar to 
the concentrations used in the current study and hence these transporters could play a role 
in modulating the membrane passage of these amines. A proton driven, ATP-independent, 
active transport process for PE has been demonstrated in Caco-2 cells (Fischer et al., 
2010). This was concluded to occur via an as yet unidentified orphan transporter, as the 
characteristics of the transport were not consistent with known transporters of organic 
cations and amino acids. The kinetics of the PE transport showed some similarities to 
those observed here, with equilibration of transport being very rapid, occurring within 5 
minutes (Fischer et al., 2010). However, there was no effect of other trace amines 
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(including tyramine) or monoamine neurotransmitters on the transport of PE. This 
suggests that there are different transport processes involved in PE and tyramine 
membrane passage, at least in intestinal epithelial cells.  
 
Tyramine and DA are endogenously synthesized in neurons (section 2.1). Therefore the 
passage of these compounds across neuronal synaptosome membranes was also 
investigated. The uptake into the synaptosomes was very quick for both tyramine and 
DA. The equilibrium occurred within 3 minutes for tyramine, with a trend for a slower 
rate of uptake with DA (Figures 22 and 23). However, in both instances this was 
sufficiently quick that rate constants for uptake could not be determined.  
Tyramine release from synaptosomes occurred significantly (p = 0.0042, F = 8.77) 
quicker than DA (figure 26) with a 71% faster rate of release. This is consistent with 
previous studies showing DA to be stored in synaptic vesicles in nerve terminals, but that 
the same does not hold for tyramine (Juorio et al., 1988). Further it is consistent with the 
previous suggestions (Paterson et al., 1990; Berry, 2004) that tyramine is released by 
simple diffusion and synaptic concentrations are in a steady state determined by the 
relative rates of synthesis and degradation. This is also consistent with the greater rate of 
membrane permeability for tyramine seen in Fluorosomes.  
High K
+
 caused a significant (p = 0.01, F = 6.95) increase in the rate of DA release but a 
slowing of the rate for tyramine (p = 0.02, F = 5.86) as shown in figures 24 and 25. 
Tyramine release in non-depolarized membranes was 61% faster than tyramine release 
under high K
+
-induced depolarization. DA release in high K
+
 was 55% greater than DA 
release across non-depolarized membranes. Under depolarizing conditions there was no 
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longer a significant difference between the rates of release of tyramine and DA. 
Depolarization of the synaptosomes results in the opening of voltage-gated calcium 
channels (Hall, 2011). The increased calcium then initiates the release of vesicle stores by 
exocytosis. As such it would be expected that a greater release of vesicle-stored 
compounds would occur under depolarizing conditions. This was seen with DA. The 
greater release of tyramine under basal conditions and lack of increased release following 
depolarization is consistent with earlier studies of Dyck (1989) showing a lack of effect 
of depolarization on tyramine release. However, in the current study a slowing of 
tyramine release was observed under depolarizing conditions. The mechanism of such an 
effect is unknown and requires further study. No other reports of a decreased release of 
compounds from synaptosomes under depolarizing conditions is currently known. 
A plateau region for tyramine release appeared to be present between 2 and 4 minutes 
(Figure 24). This could indicate two neuronal pools of tyramine.  Dyck (1989) previously 
suggested multiple pools of tyramine were present that responded differently to 
membrane depolarization. It was suggested that one of these pools may represent a 
distinct sub-form of synaptic vesicles. Although data in the current study was suggestive 
of multiple pools, a significant improvement was not observed when the data was fit to a 
2-phase exponential function. Again further studies would be required to clarify the 
nature of these apparent multiple pools of synaptic tyramine. Interestingly a similar 
apparent biphasic temporal response to trace amines in synaptosomes has been reported 
by Xie et al. (2008) during studies of the effects of trace amines on monoamine 
transporters. Whether these observations are related is unknown at present. 
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Finally when tyramine fluorosome data was compared with tyramine synaptosome data, 
membrane passage was significantly faster (F = 13.63, p = 0.0002) in Fluorosomes. A 
similar greater release was also observed for DA (F = 56.77 and p = 0.0001). This 
suggests that the presence of transporters modifies the passage of both trace amines and 
neurotransmitters across membranes. In fluorosomes which are merely phospholipid 
vesicles there are no transporters involved and it merely shows the passage of compounds 
through the membrane by passive diffusion. Synaptosomes express all of the monoamine 
transporters associated with synaptic terminals. Proteomic studies by Bai and Witzmann 
(2007) identified the various proteins present in neuronal terminals.  With respect to DA 
the DAT and VMAT2 are likely the most important and are well documented to act to 
limit synaptic concentrations of DA (Eiden et al., 2004; Bai and Witzmann, 2007). For 
tyramine there are no known selective tyramine transporters. Tyramine has however been 
reported to interact non-specifically with a number of transporter proteins. At the 
concentration used here (100 nM) tyramine has been reported to interact to a minor extent 
with NET and VMAT (Raiteri et al., 1977; Partilla et al., 2006), but is unlikely to interact 
with either DAT or SERT (Raiteri etal., 1977; Parker and Cubeddu, 1988). As such NET 
and VMAT are the most likely transporters responsible for the modification of tyramine 
transport in the current study. In addition there are a number of amino acid transporters 
present in cells (Kanai and Hediger, 2004; Palacin and Kanai, 2004). Due to the close 
structural similarity between trace amines and amino acids, it is possible that trace amines 
are transported across cell membranes by one or more of these amino acid transporters. 
Other trace amines also can interact to a minor extent with neurotransmitter transporters 
at physiological concentrations. PE interacts with DAT (Baker et al., 1976; Raiteri, 1977; 
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Parker and Cubeddu, 1988), while TRYP interacts with 5-HT (Horn, 1973; Horn, 1978; 
Baumgarten et al., 1975; Rudnick and Wall, 1992; Hilber et al., 2005). It is likely that 
these non-specific interactions will also modify the membrane transport properties of 
these trace amines. 
Trace amines have been shown to modify monoamine transporter function specifically 
through TAAR 1 binding (Xie et al., 2008; Xie and Miller, 2008). Whether TAAR1-
mediated modulation alters monoamine neurotransmitter transporter affinity for trace 
amines such as tyramine would require specific study. This could mean that at 
physiological concentrations the trace amines are substrates for membrane transporters 
following TAAR1-mediated modulation of transporter functioning. This would allow 
membrane transporters to at least partially control synaptic trace amine levels. 
Trace amines have been implicated in a number of neurological and psychiatric disorders, 
such as schizophrenia and depression  (section 2.3.4). These diseases are marked by poor 
therapeutic management in comparison to other disorders. Understanding the basal 
functioning of the trace aminergic system is therefore of potential clinical utility. The 
current data begins to address this by clarifying the mechanism by which endogenous 
ligands at TAAR can cross lipid bilayer membranes and thereby interact with TAAR. 
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6 SUMMARY AND CONCLUSION  
In this thesis trace amine membrane permeability was compared to the corresponding 
neurotransmitters in the presence and absence of membrane transporters. First 
fluorosomes were used to determine the permeability coefficients and diffusion half-lives 
in the absence of any transporters. Trace amines in general were significantly more 
permeable than the corresponding neurotransmitters. Further log P, log D7.4 and TPSA 
markers of lipophilicity were examined for their ability to predict the permeability of 
trace amines and neurotransmitters. Log D7.4 appeared more predictive than log P and 
TPSA as the ionization of compounds is maintained at pH 7.4 which also occurs 
physiologically. Caco-2 cell culture and synaptosomes were used to determine the 
permeability of [
3
H]-tyramine and [
3
H]-dopamine in the presence of membrane 
transporters. With Caco-2 cell culture a rate constant or flux could not be determined due 
to limitations of physical sampling at early time points. The results obtained with Caco-2 
cell culture did suggest that only a small fraction of administered tyramine was 
accumulated, although this was approximately twice that of DA, suggesting a role of 
membrane transporters in modifying membrane passage. In synaptosomes uptake 
equilibration was reached within 5 minutes for both tyramine and DA, although a trend to 
a slower equilibration time may have been present for DA. Tyramine release occurred 
significantly quicker than DA. In depolarized membranes there was an increase in the 
rate of DA release but not for tyramine release. All these results suggest that trace amines 
in general are more permeable than the corresponding neurotransmitters and release does 
not occur primarily through exocytosis. Finally when the transport in the absence and 
presence of transporters was directly compared (table 6) a significantly slower membrane 
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passage was observed in the presence of transporters for trace amine (tyramine) and 
neurotransmitter (DA). This means the membrane proteins or transporters limit the 
passage of trace amines across membranes under physiological conditions. 
It is possible to conclude that in general, trace amines are more permeable than the 
corresponding neurotransmitters both in the presence and absence of transporters, which 
was seen in all the systems used. Membrane passage of trace amines was in general 
consistent with physiological ‘release’ occurring by simple diffusion. However, there is 
evidence that this can be modified by the presence of membrane transporters. The nature 
of the transporters involved in this modulation of trace amine transport requires further 
study. This could be addressed by the systematic study of trace amine transport across 
isolated biological membranes such as synaptosomes, following the selective knock-out 
of genes encoding candidate transporters. Such candidate transporters could include, but 
are not limited to, DAT, NET, SERT, and the various amino acid transporters.  
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7 FUTURE DIRECTIONS 
Though it can be seen that the trace amines are more permeable than the corresponding 
neurotransmitters, the exact mechanism of membrane passage is not known. The slower 
permeability in biological membranes than in Fluorosomes suggests an involvement of 
membrane transporters. Future studies should systematically characterise the transporter 
systems involved in trace amine membrane passage. Fluorosomes can be custom made 
such that they contain a specific transporter. In addition, transporter inhibitors could be 
used to examine the role of established monoamine transporters such as DAT, NET, 
SERT and VMAT2. More compounds should be analysed for log P, TPSA and log D7.4 to 
allow a statistical comparison of correlations to fluorosomes permeability data. Finally, 
tyramine release from synaptosomes showed evidence of two pools. Previous studies 
have shown release of tyramine to be sensitive to the method used for inducing 
depolarisation. Thus, different depolarization methods can be used to begin to examine 
the nature of the putative multiple synaptic pools of tyramine.  
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